Filing Details

Accession Number:
0001567619-21-013730
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-07-20 17:54:29
Reporting Period:
2021-07-20
Accepted Time:
2021-07-20 17:54:29
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1623715 Imago Biosciences Inc. IMGO () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1365617 J Patrick Heron C/O Imago Biosciences, Inc.
329 Oyster Point Blvd, 3Rd Floor
South San Francisco CA 94080
Yes No No No
1553071 Frazier Healthcare Vii, L.p. 601 Union Street
Suite 3200
Seattle WA 98101
No No Yes No
1575192 Frazier Healthcare Vii-A, L.p. 601 Union Street
Suite 3200
Seattle WA 98101
No No Yes No
1654631 Fhm Vii, L.l.c. 601 Union Street, Suite 3200
Seattle WA 98101
No No Yes No
1654632 Fhm Vii, L.p. 601 Union Street, Suite 3200
Seattle WA 98101
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-07-20 41,582 $16.00 41,582 No 4 P Indirect See Footnote
Common Stock Acquisiton 2021-07-20 145,918 $16.00 145,918 No 4 P Indirect See Footnote
Common Stock Acquisiton 2021-07-20 341,932 $0.00 383,514 No 4 C Indirect See Footnote
Common Stock Acquisiton 2021-07-20 211,069 $0.00 594,583 No 4 C Indirect See Footnote
Common Stock Acquisiton 2021-07-20 64,360 $0.00 658,943 No 4 C Indirect See Footnote
Common Stock Acquisiton 2021-07-20 1,199,890 $0.00 1,345,808 No 4 C Indirect See Footnote
Common Stock Acquisiton 2021-07-20 740,673 $0.00 2,086,481 No 4 C Indirect See Footnote
Common Stock Acquisiton 2021-07-20 225,850 $0.00 2,312,331 No 4 C Indirect See Footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect See Footnote
No 4 P Indirect See Footnote
No 4 C Indirect See Footnote
No 4 C Indirect See Footnote
No 4 C Indirect See Footnote
No 4 C Indirect See Footnote
No 4 C Indirect See Footnote
No 4 C Indirect See Footnote
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A Preferred Stock Disposition 2021-07-20 341,932 $0.00 341,932 $0.00
Common Stock Series B Preferred Stock Disposition 2021-07-20 211,069 $0.00 211,069 $0.00
Common Stock Series C Preferred Stock Disposition 2021-07-20 64,360 $0.00 64,360 $0.00
Common Stock Series A Preferred Stock Disposition 2021-07-20 1,199,890 $0.00 1,199,890 $0.00
Common Stock Series B Preferred Stock Disposition 2021-07-20 740,673 $0.00 740,673 $0.00
Common Stock Series C Preferred Stock Disposition 2021-07-20 225,850 $0.00 225,850 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. These shares are held directly by Frazier Healthcare VII-A, L.P. ("FH VIIA"). The general partner of FH VIIA is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VIIA. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by FH VIIA, except to the extent of his or its pecuniary interest therein, if any.
  2. These shares are held directly by Frazier Healthcare VII, L.P. ("FH VII"). The general partner of FH VII is FHM VII, L.P. and the general partner of FHM VII, L.P. is FHM VII, L.L.C., and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by FH VII. The Reporting Person is one of six members of FHM VII, L.L.C. The Reporting Person, FHM VII, L.P. and FHM VII, L.L.C. each disclaim Section 16 beneficial ownership of the securities held by FH VII, except to the extent of his or its pecuniary interest therein, if any.
  3. Each share of the Issuer's Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering on July 20, 2021 and had no expiration date.